𝔖 Bobbio Scriptorium
✦   LIBER   ✦

AVAPERL (MO22089): Final Efficacy Outcomes for Patients (pts) With Advanced Non-squamous Non-small Cell Lung Cancer (nsNSCLC) Randomised to Continuation Maintenance (mtc) with Bevacizumab (bev) or Bev + Pemetrexed (pern) After First-line (1L) Bev-cisplatin (cis)-pem Treatment (Tx)

✍ Scribed by F Barlesi; J. de Castro; V. Dvornichenko; J.H. Kim; A. Pazzola; A. Rittmeyer; A. Vikström; L. Mitchell; E.K. Wong; V. Gorbunova


Book ID
117660632
Publisher
Elsevier Science
Year
2011
Tongue
English
Weight
48 KB
Volume
47
Category
Article
ISSN
0959-8049

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES